Processing...
Clinical Trials for Ovarian Cancer
Search
Search
There are 200 active trials for advanced/metastatic ovarian cancer.
Click on a trial to see more information.
200 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with advanced, measurable solid tumors and assessable MUC1 and/or HER3 expression are eligible to receive DM002, a bispecific antibody-drug conjugate targeting MUC1 and HER3, given intravenously every three weeks.
ClinicalTrials.gov ID: NCT06751329
TrialFetch AI summary: This trial enrolls adults with peritoneal carcinomatosis from ovarian, uterine, gastric, appendiceal, or colorectal cancer who have progressed after at least one prior chemotherapy, testing the safety and efficacy of PIPAC (pressurized intraperitoneal aerosol chemotherapy) with standard agents (doxorubicin/cisplatin, oxaliplatin, or mitomycin plus FOLFIRI) according to tumor type and prior treatment. PIPAC aims to enhance local drug exposure in the peritoneum while potentially reducing systemic toxicity.
ClinicalTrials.gov ID: NCT04329494
TrialFetch AI summary: This trial enrolls adults with advanced, FAP-positive solid tumors who have progressed on or lack standard therapy, using [203Pb]Pb-PSV359 SPECT imaging to confirm FAP expression and [212Pb]Pb-PSV359, a FAP-targeted alpha-emitting peptide-radiopharmaceutical, for systemic therapy.
ClinicalTrials.gov ID: NCT06710756
TrialFetch AI summary: Adults with advanced solid tumors receive first-in-human BMS-986500 monotherapy (with a dedicated expansion for CCNE1-amplified ovarian cancer); separate cohorts enroll advanced breast cancer previously treated with a CDK4/6 inhibitor to receive BMS-986500 combined with palbociclib plus fulvestrant. BMS-986500’s molecular target/mechanism is undisclosed; the study focuses on safety/PK and dose finding with exploratory efficacy by RECIST.
ClinicalTrials.gov ID: NCT06997029
TrialFetch AI summary: Adults with advanced/metastatic breast, ovarian, or prostate cancer (including patients with known brain metastases), ECOG 0–1, and measurable disease receive oral DSB2455, a PARP1‑selective inhibitor aiming to exploit synthetic lethality in HR‑deficient tumors (e.g., BRCA/HRR alterations); prior first‑line PARP inhibitor exposure is allowed, but prior PARP1‑selective therapy is excluded. Single‑arm dose escalation/expansion evaluates safety and preliminary activity, with CNS penetration highlighted and mandatory biopsies required.
ClinicalTrials.gov ID: NCT06458712
TrialFetch AI summary: Adults with metastatic or unresectable solid tumors harboring AKT/PI3K/PTEN pathway alterations (excluding concurrent EGFR/KRAS/NRAS/HRAS/BRAF drivers) receive the investigational AKT-pathway inhibitor TER-2013 as monotherapy (expansion in ovarian/cervical/SCCHN/lung/esophageal and endometrial cancers) or with fulvestrant for HR+/HER2- breast cancer previously treated with an aromatase inhibitor. Prior AKT/PI3K/PTEN inhibitors (and prior SERD/mTOR in combo expansion) are excluded; requires ECOG 0–1 and adequate organ function.
ClinicalTrials.gov ID: NCT07109726
TrialFetch AI summary: Adults with mesothelin-expressing advanced solid tumors (ECOG 0–1) receive weekly IV CT-95 (LNK-101), a mesothelin × CD3 T‑cell–engaging bispecific antibody engineered for reduced off‑tumor activation, in a dose-escalation/expansion study. Excludes prior mesothelin-targeted CD3/CAR‑T therapy; evaluates safety, PK, and preliminary efficacy across tumor types including mesothelioma.
ClinicalTrials.gov ID: NCT06756035
TrialFetch AI summary: Adults with mesothelin-expressing recurrent/relapsed advanced ovarian (including primary peritoneal/fallopian tube), cholangiocarcinoma, or epithelial mesothelioma (pleural/peritoneal), ECOG 0–1, after ≥1 prior therapy, receive lymphodepleting chemotherapy followed by a single infusion of SynKIR-110, an autologous T-cell therapy using a mesothelin-targeted KIR-CAR (activating KIR plus DAP12) designed to enhance persistence/function in solid tumors. Excludes prior gene-engineered T-cell therapy, sarcomatoid/biphasic mesothelioma, active viral infections, significant pulmonary disease, and active autoimmune disease.
ClinicalTrials.gov ID: NCT05568680
TrialFetch AI summary: Adults with TROP2-positive, platinum-resistant ovarian/peritoneal/fallopian tube cancer, mesonephric-like adenocarcinoma, or pancreatic/ampullary cancer with peritoneal/retroperitoneal disease receive lymphodepleting cyclophosphamide/fludarabine followed by a single intraperitoneal infusion of allogeneic cord blood–derived NK cells engineered with a TROP2-directed CAR and IL-15 for persistence. Designed to assess safety and preliminary efficacy of intraperitoneal TROP2 CAR-NK in heavily pretreated patients without active CNS disease or contraindications to IP therapy.
ClinicalTrials.gov ID: NCT05922930
TrialFetch AI summary: Adults with CLDN6-positive advanced solid tumors—emphasizing platinum-resistant/refractory ovarian cancer (also endometrial or testicular)—with measurable disease and ECOG 0–2 receive weekly IV CTIM-76, a CLDN6×CD3 T cell–engaging bispecific antibody, in dose escalation and expansion cohorts. Excludes active/untreated CNS disease, prior CLDN6 therapy, uncontrolled infection; treatment continues until progression or toxicity.
ClinicalTrials.gov ID: NCT06515613